Additionally to dextometorphan, the mixed S1R and muscarinic receptor agonist ANAVEX2-73 (Blarcamesine), can also provide protection for oligodendrocytes and oligodendrocytes precursors and promote reparative therapy in MS [54]. The gene discussed is TMBIM4; the disease is myeloid sarcoma.